Clinical Oral Investigations

, Volume 23, Issue 3, pp 1407–1414 | Cite as

Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren’s syndrome: a pilot study

  • Asta TvarijonaviciuteEmail author
  • Carmen Zamora
  • Silvia Martinez-Subiela
  • Fernando Tecles
  • Francisca Pina
  • Pia Lopez-Jornet
Original Article



To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren’s syndrome (SS).


Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed.


Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADA was higher in patients with SS and non-SS sicca compared to controls (P < 0.05 in both cases).


The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS.

Clinical relevance

Salivary adiponectin corrected by total protein can be a potential biomarker of SS.

Trial registration



Adiponectin Adenosine deaminase Biomarker Clinical signs Xerostomia Saliva 



AT was financially supported by the Program “Juan de la Cierva Incorporacion” of “Ministerio de Economia y Competitividad,” Spain, through a post-doctoral grant.

Author contribution

AT, PLJ, FT, and SMS designed the study; PLJ, FP, and CZ collected the samples; AT, FT, and SMS analysed the samples; AT, PLJ, FT, and SMS analysed the data; AT, PLJ, FT, and SMS drafted, revised, and approved the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Guggenheimer J, Moore PA (2003) Xerostomia: etiology, recognition and treatment. J Am Dent Assoc 134:61–69. CrossRefGoogle Scholar
  2. 2.
    Villa A, Wolff A, Narayana N et al (2016) World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis 22:365–382. CrossRefGoogle Scholar
  3. 3.
    Ergun S, Çekici A, Topcuoglu N et al (2010) Oral status and Candida colonization in patients with Sjögren’s syndrome. Med Oral Patol Oral Cir Bucal Mar 11515:310–315. CrossRefGoogle Scholar
  4. 4.
    Manoussakis MN, Moutsopoulos HM (2000) Sjögren’s syndrome: autoimmune epithelitis. Best Pract Res Clin Rheumatol 14:73–95. CrossRefGoogle Scholar
  5. 5.
    Fox RI (2005) Sjögren’s syndrome. Lancet (London, England) 366:321–331. CrossRefGoogle Scholar
  6. 6.
    Delaleu N, Jonsson MV, Appel S, Jonsson R (2008) New concepts in the pathogenesis of Sjögren’s syndrome. Rheum Dis Clin N Am 34:833–845, vii. CrossRefGoogle Scholar
  7. 7.
    Katsiougiannis S, Wong DTW (2016) The proteomics of saliva in Sjögren’s syndrome. Rheum Dis Clin N Am 42:449–456. CrossRefGoogle Scholar
  8. 8.
    Rhodus N, Dahmer L, Lindemann K et al (1998) s-IgA and cytokine levels in whole saliva of Sjögren’s syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study. Clin Oral Investig 2:191–196. CrossRefGoogle Scholar
  9. 9.
    Kang EH, Lee YJ, Hyon JY et al (2011) Salivary cytokine profiles in primary Sjögren’s syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 29:970–976Google Scholar
  10. 10.
    Katsiougiannis S, Kapsogeorgou EK, Manoussakis MN, Skopouli FN (2006) Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum 54:2295–2299. CrossRefGoogle Scholar
  11. 11.
    De Sanctis JB, Zabaleta M, Bianco NE et al (2009) Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42:272–274. CrossRefGoogle Scholar
  12. 12.
    Zamani B, Jamali R, Jamali A (2012) Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int 32:1967–1975. CrossRefGoogle Scholar
  13. 13.
    Salesi M, Ghazvini RA, Farajzadegan Z et al (2012) Serum adenosine deaminase in patients with rheumatoid arthritis treated with methotrexate. J Res Pharm Pract 1:72–76. CrossRefGoogle Scholar
  14. 14.
    Saghiri R, Ghashghai N, Movaseghi S et al (2012) Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int 32:1633–1638. CrossRefGoogle Scholar
  15. 15.
    Torgutalp M, Efe C, Babaoglu H, Kav T (2017) Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis. World J Gastroenterol 23:3876–3882. CrossRefGoogle Scholar
  16. 16.
    Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26:439–451. CrossRefGoogle Scholar
  17. 17.
    Su Y-C, Xiang R-L, Zhang Y et al (2013) Decreased submandibular adiponectin is involved in the progression of autoimmune sialoadenitis in non-obese diabetic mice. Oral Dis 20:n/a. CrossRefGoogle Scholar
  18. 18.
    Iizuka H, Koizumi H, Kamigaki K et al (1981) Two forms of adenosine deaminase in pig epidermis. J Dermatol 8:91–95. CrossRefGoogle Scholar
  19. 19.
    MacDermott RP, Tritsch GL, Formeister JF (1980) Adenosine deaminase and nucleoside phosphorylase activities in normal human blood mononuclear cell subpopulations. Clin Exp Immunol 42:303–307Google Scholar
  20. 20.
    Sullivan JL, Osborne WRA, Wedgwood RJ (1977) Adenosine deaminase activity in lymphocytes. Br J Haematol 37:157–158. CrossRefGoogle Scholar
  21. 21.
    Rai B, Kaur J, Jacobs R, Anand SC (2011) Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue. Clin Oral Investig 15:347–349. CrossRefGoogle Scholar
  22. 22.
    Saracoglu U, Guven O, Durak I (2005) Adenosine deaminase and 5′-nucleotidase activities in saliva from patients with oral and laryngeal cancer. Oral Dis 11:323–325. CrossRefGoogle Scholar
  23. 23.
    Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. CrossRefGoogle Scholar
  24. 24.
    Löe H (1967) The gingival index, the plaque index and the retention index systems. J Periodontol 38:610–616. CrossRefGoogle Scholar
  25. 25.
    Thomson WM (2007) Measuring change in dry-mouth symptoms over time using the xerostomia inventory. Gerodontology 24:30–35. CrossRefGoogle Scholar
  26. 26.
    Tvarijonaviciute A, Aznar-Cayuela C, Rubio CP et al (2017) Evaluation of salivary oxidate stress biomarkers, nitric oxide and C-reactive protein in patients with oral lichen planus and burning mouth syndrome. J Oral Pathol Med 46:387–392. CrossRefGoogle Scholar
  27. 27.
    Tvarijonaviciute A, Castillo C, Ceron JJ et al (2017) Leptin and NGF in saliva of patients with diabetes mellitus type 2: a pilot study. J Oral Pathol Med 46:853–855. CrossRefGoogle Scholar
  28. 28.
    Lopez-Jornet P, Cayuela CA, Tvarijonaviciute A et al (2016) Oral lichen planus: salival biomarkers cortisol, immunoglobulin A, adiponectin. J Oral Pathol Med 45:211–217. CrossRefGoogle Scholar
  29. 29.
    Delacour H, Bousquet A, Fontan E, Ceppa F (2013) Ammonia does not interfere with the Diazyme adenosine deaminase test. Clin Chem Lab Med 51:e225–e226. CrossRefGoogle Scholar
  30. 30.
    Toussirot E, Gaugler B, Bouhaddi M et al (2010) Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediat Inflamm 2010(938408):–6.
  31. 31.
    Augusto KL, Bonfa E, Pereira RMR et al (2016) Metabolic syndrome in Sjögren’s syndrome patients: a relevant concern for clinical monitoring. Clin Rheumatol 35:639–647. CrossRefGoogle Scholar
  32. 32.
    Contreras-Aguilar MD, Escribano D, Martínez-Subiela S et al (2017) Influence of the way of reporting alpha-amylase values in saliva in different naturalistic situations: a pilot study. PLoS One 12:e0180100. CrossRefGoogle Scholar
  33. 33.
    Barranco T, Tvarijonaviciute A, Tecles F, et al. (2017) Changes in CK, LDH and AST in saliva samples after an intense exercise: a pilot study. J Sports Med Phys Fitness. doi:
  34. 34.
    Sasaki T, Nakajima H (1992) Serum adenosine deaminase activity in systemic sclerosis (scleroderma) and related disorders. J Am Acad Dermatol 27:411–414. CrossRefGoogle Scholar
  35. 35.
    Herken H, Gurel A, Selek S et al (2007) Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 38:247–252CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Interdisciplinary Laboratory of Clinical Analysis Interlab-UMU, Faculty of Veterinary Medicine, Regional Campus of International Excellence ‘Campus Mare Nostrum’University of MurciaMurciaSpain
  2. 2.Department of Oral Medicine, Faculty of Medicine, Regional Campus of International Excellence ‘Campus Mare Nostrum’University of MurciaMurciaSpain
  3. 3.Department of RheumatologyMorales Meseguer General University HospitalMurciaSpain

Personalised recommendations